Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers

We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositi...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Ryosuke, Ikemura, Sumie, Jinta, Torahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985661/
https://www.ncbi.nlm.nih.gov/pubmed/33777398
http://dx.doi.org/10.1002/rcr2.736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985661/
https://www.ncbi.nlm.nih.gov/pubmed/33777398
http://dx.doi.org/10.1002/rcr2.736

Ejemplares similares